MCID: FTT001
MIFTS: 59

Fatty Liver Disease malady

Categories: Gastrointestinal diseases, Metabolic diseases, Liver diseases

Aliases & Classifications for Fatty Liver Disease

Aliases & Descriptions for Fatty Liver Disease:

Name: Fatty Liver Disease 12 41 14
Fatty Liver, Alcoholic 42 69
Alcoholic Fatty Liver 12 14
Fatty Liver 42 69
Fatty Change of Liver 12
Fatty Liver Alcoholic 52
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9452
ICD10 33 K70.0
ICD9CM 35 571.0

Summaries for Fatty Liver Disease

MedlinePlus : 41 what is fatty liver disease? your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. fatty liver disease is a condition in which fat builds up in your liver. there are two main types: nonalcoholic fatty liver disease (nafld) alcoholic fatty liver disease, also called alcoholic steatohepatitis what is nonalcoholic fatty liver disease (nafld)? nafld is a type of fatty liver disease that is not related to heavy alcohol use. there are two kinds: simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. simple fatty liver typically does not get bad enough to cause liver damage or complications. nonalcoholic steatohepatitis (nash), in which you have inflammation and liver cell damage, as well as fat in your liver. inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. nash may lead to cirrhosis or liver cancer. what is alcoholic fatty liver disease? alcoholic fatty liver disease is due to heavy alcohol use. your liver breaks down most of the alcohol you drink, so it can be removed from your body. but the process of breaking it down can generate harmful substances. these substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. the more alcohol that you drink, the more you damage your liver. alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. the next stages are alcoholic hepatitis and cirrhosis. who gets fatty liver disease? researchers do not know the cause of nonalcoholic fatty liver (nafld). they do know that it is more common in people who have type 2 diabetes and prediabetes are obese are middle aged or older (although children can also get it) are hispanic, followed by non-hispanic whites. it is less common in african americans. have high levels of fats in the blood, such as cholesterol and triglycerides have high blood pressure take certain drugs, such as corticosteroids and some cancer drugs have certain metabolic disorders, including metabolic syndrome have rapid weight loss have certain infections, such as hepatitis c have been exposed to some toxins nafld affects about 25 percent of people in the world. as the rates of obesity, type 2 diabetes, and high cholesterol are rising in the united states, so is the rate of nafld. nafld is the most common chronic liver disorder in the united states. alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. the risk is higher for heavy drinkers who are women, are obese, or have certain genetic mutations. what are the symptoms of fatty liver disease? both nafld and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. if you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. how do i know if i have fatty liver disease? because there are often no symptoms, it is not easy to find fatty liver disease. your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. to make a diagnosis, your doctor will use your medical history a physical exam various tests, including blood and imaging tests, and sometimes a biopsy as part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (nafld). he or she will also ask which medicines you take, to try to determine whether a medicine is causing your nafld. during the physical exam, your doctor will examine your body and check your weight and height. your doctor will look for signs of fatty liver disease, such as an enlarged liver signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow you will likely have blood tests, including liver function tests and blood count tests. in some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. liver stiffness can mean fibrosis, which is scarring of the liver. in some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. what are the treatments for fatty liver disease? doctors recommend weight loss for nonalcoholic fatty liver. weight loss can reduce fat in the liver, inflammation, and fibrosis. if your doctor thinks that a certain medicine is the cause of your nafld, you should stop taking that medicine. but check with your doctor before stopping the medicine. you may need to get off the medicine gradually, and you might need to switch to another medicine instead. there are no medicines that have been approved to treat nafld. studies are investigating whether a certain diabetes medicine or vitamin e can help, but more studies are needed. the most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. if you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. there are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. if the cirrhosis leads to liver failure, you may need a liver transplant. what are some lifestyle changes that can help with fatty liver disease? if you have any of the types of fatty liver disease, there are some lifestyle changes that can help: eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains get vaccinations for hepatitis a and b, the flu and pneumococcal disease. if you get hepatitis a or b along with fatty liver, it is more likely to lead to liver failure. people with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. get regular exercise, which can help you lose weight and reduce fat in the liver talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, alcoholic, is related to fatty liver disease, nonalcoholic 1 and fatty liver disease, nonalcoholic 2. An important gene associated with Fatty Liver Disease is ADIPOQ (Adiponectin, C1Q And Collagen Domain Containing), and among its related pathways/superpathways are PEDF Induced Signaling and Developmental Biology. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Related Diseases for Fatty Liver Disease

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
id Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 12.4
2 fatty liver disease, nonalcoholic 2 12.1
3 pnpla3-related susceptibility to nonalchoholic fatty liver disease 12.0
4 nonalcoholic steatohepatitis 11.9
5 liver disease 11.6
6 visceral steatosis 11.0
7 morbid obesity and spermatogenic failure 10.7
8 obesity 10.6
9 hepatitis 10.5
10 autosomal recessive congenital ichthyosis 10.3 INS LEP PPARA
11 nystagmus, congenital motor, autosomal recessive 10.3 ADIPOQ LEP TNF
12 iida kannari syndrome 10.3 ADIPOQ INS PPARA
13 leg dermatosis 10.3 ADIPOQ INS LEP
14 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
15 joint disorders 10.3 IL6 INS TNF
16 cataract 20, multiple types 10.3 ADIPOQ INS LEP PPARA
17 bladder sarcoma 10.3 IL6 LEP TNF
18 mononeuritis of lower limb 10.3 ADIPOQ INS PNPLA3 SREBF1
19 acrocephalopolydactyly 10.3 ADIPOQ LEP
20 lipomatosis 10.3 ADIPOQ INS LEP PPARA
21 hyperlipoproteinemia type iv 10.3 ADIPOQ IL6 INS LEP
22 exophthalmic ophthalmoplegia 10.3 ADIPOQ LEP LEPR
23 posterior uveal melanoma 10.3 ADIPOQ INS PNPLA3 SREBF1
24 mucopolysaccharidosis iii 10.3 ADIPOQ INS LEP LEPR
25 chondroma 10.3 IL6 INS LEP TNF
26 mucinoses 10.2 ADIPOQ IL6 LEP MLXIPL
27 myelophthisic anemia 10.2 ADIPOQ IL6 INS PPARA
28 amelogenesis imperfecta 10.2 CYP2E1 IL6 TNF
29 not otherwise specified 3-mga-uria type 10.2 ADIPOQ CYP2E1 INS LEP PPARA
30 vogt-koyanagi-harada disease 10.2 CASP3 IL6 TNF
31 neurogenic arthropathy 10.2 ADIPOQ INS IRS1 LEP
32 pyrimidine metabolic disorder 10.2 ADIPOQ IL6 INS TNF
33 immunoglobulin g deficiency 10.2 CASP3 IL6 TNF
34 brain stem glioma 10.2 ADIPOQ INS IRS1 LEP
35 spondylolysis 10.2 IL6 INS TNF
36 familial nephrotic syndrome 10.2 IL6 LEP TNF
37 autoimmune-related retinopathy and optic neuropathy 10.2 ADIPOQ IL6 INS TNF
38 limb ischemia 10.1 ADIPOQ IL6 INS LEP LEPR TNF
39 atherosclerosis 10.1
40 diabetic encephalopathy 10.1 ADIPOQ IL6 INS LEP LEPR TNF
41 blind loop syndrome 10.1 ADIPOQ INS IRS1 LEP LEPR
42 splenic marginal zone lymphoma 10.1 CASP3 IL6 TNF
43 cholesteatoma 10.1 ADIPOQ LEP LEPR
44 hepatitis c 10.1
45 substance-induced psychosis 10.1 CASP3 IL6 INS TNF
46 edict syndrome 10.1 INS IRS1 IRS2 LEP
47 hepatocellular carcinoma 10.1
48 antidepressant type abuse 10.0 ADIPOQ ADIPOR1 INS IRS1 IRS2 LEP
49 diabetes mellitus, insulin-dependent, 20 10.0 ADIPOQ IL6 INS IRS1 LEP LEPR
50 artery disease 10.0

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 IRS2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.74 LEP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.74 XBP1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.74 LEP NR1H3 XBP1 IRS2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.74 XBP1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.74 XBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 XBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 IRS2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.74 NR1H3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.74 XBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.74 NR1H3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 LEP XBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 NR1H3 IRS2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.74 NR1H3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.74 IRS2 XBP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 NR1H3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 IRS2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.74 NR1H3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.74 IRS2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.74 IRS2
21 Increased cell death HMECs cells GR00103-A-0 9.63 ATF4 CASP3 INS IRS1 MAPK8 NR1H3
22 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CASP3 INS MAPK8 TNF

MGI Mouse Phenotypes related to Fatty Liver Disease:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.51 MAPK8 MLXIPL NR1H3 PNPLA3 PPARA SREBF1
2 cardiovascular system MP:0005385 10.45 ADIPOQ ATF4 CASP3 CYP2E1 IL6 INS
3 adipose tissue MP:0005375 10.44 ADIPOQ ADIPOR1 ADIPOR2 ATF4 IL6 INS
4 cellular MP:0005384 10.44 ATF4 CASP3 IL6 INS IRS1 IRS2
5 behavior/neurological MP:0005386 10.43 ADIPOQ CYP2E1 IL6 INS IRS2 LEP
6 growth/size/body region MP:0005378 10.41 ATF4 CASP3 IL6 INS IRS1 IRS2
7 liver/biliary system MP:0005370 10.41 SREBF1 TNF XBP1 ADIPOQ ADIPOR1 ADIPOR2
8 endocrine/exocrine gland MP:0005379 10.39 INS IRS1 IRS2 LEP LEPR MAPK8
9 mortality/aging MP:0010768 10.36 XBP1 ADIPOQ ATF4 CASP3 CYP2E1 IL6
10 immune system MP:0005387 10.31 ADIPOQ CASP3 IL6 INS IRS1 IRS2
11 hematopoietic system MP:0005397 10.3 INS IRS1 LEP LEPR MAPK8 NR1H3
12 muscle MP:0005369 10.28 ADIPOQ ADIPOR1 ATF4 CASP3 IRS1 IRS2
13 integument MP:0010771 10.26 ADIPOQ ATF4 CASP3 IL6 INS IRS2
14 digestive/alimentary MP:0005381 10.21 ATF4 CASP3 IL6 INS LEP LEPR
15 nervous system MP:0003631 10.1 ADIPOR2 ATF4 CASP3 IL6 INS IRS2
16 neoplasm MP:0002006 9.91 ADIPOQ CYP2E1 IL6 LEP LEPR MAPK8
17 reproductive system MP:0005389 9.9 LEP LEPR MAPK8 NR1H3 TNF ADIPOR2
18 renal/urinary system MP:0005367 9.86 ADIPOQ CASP3 IL6 INS IRS2 LEP
19 skeleton MP:0005390 9.73 ADIPOQ ADIPOR1 ADIPOR2 ATF4 CASP3 IL6
20 vision/eye MP:0005391 9.32 ADIPOR1 ATF4 CASP3 IL6 INS LEP

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 1 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
6
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
7
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
8
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
10
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
11
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
13
Amlodipine Approved Phase 4 88150-42-9 2162
14
Glycerol Approved, Experimental Phase 4 56-81-5 753
15
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
17
Isoniazid Approved Phase 4,Phase 2,Phase 3,Phase 1 54-85-3 3767
18
Pyrazinamide Approved Phase 4,Phase 2,Phase 3,Phase 1 98-96-4 1046
19
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
20
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
21
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
22
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
23
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
24
Tamoxifen Approved Phase 4 10540-29-1 2733526
25
Gliclazide Approved Phase 4 21187-98-4 3475
26
Glipizide Approved Phase 4 29094-61-9 3478
27
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
28
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
29
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
30
Selenium Approved, Vet_approved Phase 4 7782-49-2
31
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
32
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
33
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
34
Menthol Approved Phase 4 2216-51-5 16666
35
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
36
Insulin Aspart Approved Phase 4 116094-23-6 16132418
37
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
38
Insulin Detemir Approved Phase 4 169148-63-4 5311023
39
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
40
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
41
Glimepiride Approved Phase 4 93479-97-1 3476
42
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
43
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
46
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
47
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
48
Calcium carbonate Approved Phase 4 471-34-1
49
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
50
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 870)
id Name Status NCT ID Phase
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
2 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
3 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4
4 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
5 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
6 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
7 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
8 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
10 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
11 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
12 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
13 Fat, Inflammation and Insulin Resistance Unknown status NCT01054989 Phase 4
14 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4
15 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4
16 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4
17 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4
18 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4
19 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4
20 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4
21 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4
22 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4
23 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4
24 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4
25 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
26 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4
27 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4
28 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4
29 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4
30 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4
31 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4
32 Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer Completed NCT02321202 Phase 4
33 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4
34 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
35 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4
36 Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure Completed NCT00522730 Phase 4
37 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4
38 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
39 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Completed NCT00081497 Phase 4
40 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4
41 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4
42 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. Completed NCT00545233 Phase 4
43 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
44 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed NCT00845182 Phase 4
45 Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes Completed NCT01432405 Phase 4
46 Effect of Exenatide on Liver and Heart Fat and Inflammation Completed NCT01951651 Phase 4
47 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4
48 Effects of Metformin on Hepatic FFA Metabolism Completed NCT01729156 Phase 4
49 Glucagon Efficiency After High and Low Carbohydrate Diet Completed NCT02578498 Phase 4
50 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

MalaCards organs/tissues related to Fatty Liver Disease:

39
Liver, Testes, Skin, Eye, Endothelial, Ovary, Heart

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 1360)
id Title Authors Year
1
Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by (18)F-fluorodeoxyglucose positron emission tomography. ( 28081780 )
2017
2
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( 28521870 )
2017
3
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. ( 28521774 )
2017
4
Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. ( 28081779 )
2017
5
Modulation of the gut microbiota impacts non-alcoholic fatty liver disease: a potential role for bile acids. ( 28533304 )
2017
6
The PNPLA3 Variant Associated with Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation. ( 28520213 )
2017
7
Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. ( 28086768 )
2017
8
Endocrine-disrupting chemicals and fatty liver disease. ( 28524171 )
2017
9
Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. ( 27908400 )
2017
10
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens. ( 28077733 )
2017
11
High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. ( 28487551 )
2017
12
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
13
Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. ( 28473851 )
2017
14
Author Reply-Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091895 )
2017
15
Metabolic effects of Crocus sativus and protective action against non-alcoholic fatty liver disease in diabetic rats. ( 28529733 )
2017
16
Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. ( 28533672 )
2017
17
Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. ( 28521872 )
2017
18
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease. ( 28092906 )
2017
19
Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091896 )
2017
20
The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm. ( 28079806 )
2017
21
An extended fatty liver index to predict non-alcoholic fatty liver disease. ( 28089502 )
2017
22
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. ( 28526997 )
2017
23
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. ( 28326329 )
2017
24
Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes. ( 28082742 )
2017
25
Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. ( 28527877 )
2017
26
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. ( 28074505 )
2017
27
Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. ( 28206970 )
2017
28
Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. ( 27889912 )
2017
29
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
30
Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. ( 28527304 )
2017
31
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. ( 28074504 )
2017
32
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. ( 28523578 )
2017
33
P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. ( 28318371 )
2017
34
Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. ( 27657935 )
2016
35
Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus. ( 27649152 )
2016
36
Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. ( 26362060 )
2016
37
Role of I^-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease. ( 26997011 )
2016
38
Association between adiponectin gene T45G polymorphism and nonalcoholic fatty liver disease risk: a meta-analysis. ( 26909902 )
2016
39
Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease. ( 26980291 )
2016
40
Lycopene Improves Diet-Mediated Recuperation in Rat Model of Nonalcoholic Fatty Liver Disease. ( 27214602 )
2016
41
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. ( 28089090 )
2016
42
Replication analysis of genetic association of the NCAN-CILP2 region with plasma lipid levels and non-alcoholic fatty liver disease in Asian and Pacific ethnic groups. ( 26758378 )
2016
43
Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. ( 27648297 )
2016
44
The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease. ( 27214654 )
2016
45
Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. ( 27834919 )
2016
46
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. ( 26850495 )
2016
47
Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity. ( 27832630 )
2016
48
Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease. ( 27656480 )
2016
49
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. ( 27218012 )
2016
50
PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. ( 27128907 )
2016

Variations for Fatty Liver Disease

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 49)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 ATF4 CASP3 IL6 INS LEP LEPR
2
Show member pathways
13.52 ADIPOQ INS IRS1 IRS2 LEP PPARA
3
Show member pathways
13.5 ADIPOQ ADIPOR1 ADIPOR2 ATF4 CASP3 CYP2E1
4
Show member pathways
12.78 ADIPOQ IL6 INS IRS1 IRS2 LEP
5
Show member pathways
12.54 INS IRS1 IRS2 MAPK8 MLXIPL NR1H3
6 12.51 ADIPOQ ATF4 INS IRS1 IRS2 SREBF1
7
Show member pathways
12.49 CASP3 INS IRS1 IRS2 LEP LEPR
8
Show member pathways
12.44 ADIPOQ ADIPOR1 ADIPOR2 INS IRS1 IRS2
9 12.43 ATF4 IL6 MAPK8 TNF XBP1
10
Show member pathways
12.36 ADIPOQ ADIPOR1 ADIPOR2 INS MLXIPL
11
Show member pathways
12.33 CASP3 IL6 MAPK8 TNF
13
Show member pathways
12.31 ATF4 IL6 IRS1 IRS2
14
Show member pathways
12.27 ATF4 IL6 MAPK8 TNF
15
Show member pathways
12.27 CASP3 IRS1 MAPK8 SREBF1 TNF
16 12.24 CASP3 IL6 MAPK8 TNF
17
Show member pathways
12.21 INS IRS1 IRS2 LEP
18
Show member pathways
12.19 ATF4 IRS1 IRS2 MAPK8
19
Show member pathways
12.16 ADIPOQ ADIPOR1 ADIPOR2 ATF4 INS IRS1
20
Show member pathways
12.14 CASP3 IRS1 MAPK8 TNF
21 12.12 CASP3 IRS1 IRS2 MAPK8
22 12.12 ADIPOQ IL6 INS IRS1 IRS2 LEP
23 12.07 MAPK8 NR1H3 PPARA TNF
24
Show member pathways
12.07 IL6 INS IRS1 IRS2 MAPK8
25 12.05 INS IRS1 IRS2 MAPK8
26
Show member pathways
12.02 ATF4 CASP3 MAPK8 TNF
27 12.01 CASP3 IL6 LEP TNF
28 11.94 ATF4 CASP3 IL6 MAPK8 TNF
29
Show member pathways
11.94 ADIPOQ INS IRS1 IRS2 MAPK8 TNF
30 11.91 CASP3 IL6 MAPK8 TNF
31 11.89 ADIPOQ IL6 INS LEP
32 11.77 CASP3 IL6 MAPK8 TNF
33 11.74 ADIPOQ NR1H3 PPARA
34 11.72 IL6 TNF XBP1
35 11.7 CASP3 INS IRS1 MAPK8
36 11.69 ADIPOQ ADIPOR1 ADIPOR2 IRS1 IRS2 LEP
37
Show member pathways
11.69 IL6 INS IRS1 IRS2 MAPK8 MLXIPL
38 11.6 IL6 INS MAPK8
39 11.6 CASP3 IL6 TNF
40 11.59 INS IRS1 IRS2
41 11.57 IRS1 IRS2 LEP LEPR
42 11.55 CASP3 IL6 MAPK8
43 11.55 IL6 MAPK8 TNF
44 11.52 INS IRS1 LEP LEPR
45 11.41 IRS1 IRS2 MAPK8
46 11.37 IRS1 MLXIPL SREBF1
47 11.36 CYP2E1 NR1H3 PPARA
48 11.05 NR1H3 PPARA SREBF1
49 10.51 ADIPOQ IL6 IRS1 IRS2 LEP MAPK8

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.99 ADIPOQ CASP3 LEP PPARA
2 wound healing GO:0042060 9.94 CASP3 IL6 INS PPARA
3 circadian rhythm GO:0007623 9.93 ADIPOQ ATF4 LEP SREBF1
4 positive regulation of protein kinase B signaling GO:0051897 9.93 IL6 INS LEP TNF
5 insulin receptor signaling pathway GO:0008286 9.92 INS IRS1 IRS2 SREBF1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.91 ADIPOQ IL6 INS
7 cholesterol metabolic process GO:0008203 9.91 LEP LEPR SREBF1
8 response to glucocorticoid GO:0051384 9.91 ADIPOQ CASP3 IL6 TNF
9 response to glucose GO:0009749 9.91 ADIPOQ CASP3 IRS2 SREBF1
10 positive regulation of MAPK cascade GO:0043410 9.9 IL6 INS LEP
11 response to nutrient GO:0007584 9.89 ADIPOQ ADIPOR2 LEP
12 negative regulation of inflammatory response GO:0050728 9.89 ADIPOQ NR1H3 PPARA
13 regulation of insulin secretion GO:0050796 9.88 LEP SREBF1 TNF
14 response to insulin GO:0032868 9.88 IL6 IRS1 LEP PPARA
15 response to nutrient levels GO:0031667 9.87 ADIPOQ IL6 LEP
16 regulation of circadian rhythm GO:0042752 9.86 MAPK8 NR1H3 PPARA
17 intracellular receptor signaling pathway GO:0030522 9.85 NR1H3 PPARA SREBF1
18 negative regulation of fat cell differentiation GO:0045599 9.85 ADIPOQ IL6 TNF
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IL6 INS TNF
20 lipid homeostasis GO:0055088 9.83 IRS2 NR1H3 PNPLA3
21 cellular response to lipopolysaccharide GO:0071222 9.83 IL6 MAPK8 NR1H3 TNF XBP1
22 positive regulation of JAK-STAT cascade GO:0046427 9.79 ADIPOR1 IL6 LEP
23 positive regulation of cellular protein metabolic process GO:0032270 9.77 ADIPOQ INS NR1H3
24 cellular response to insulin stimulus GO:0032869 9.77 ADIPOQ IRS1 IRS2 SREBF1 XBP1
25 positive regulation of glycogen biosynthetic process GO:0045725 9.75 INS IRS1 IRS2
26 fatty acid oxidation GO:0019395 9.74 ADIPOQ ADIPOR1 ADIPOR2
27 positive regulation of lipid biosynthetic process GO:0046889 9.73 INS MLXIPL
28 negative regulation of glucose import GO:0046325 9.73 LEP TNF
29 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 ADIPOQ NR1H3 PPARA
30 positive regulation of fatty acid biosynthetic process GO:0045723 9.72 MLXIPL NR1H3
31 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL6 XBP1
32 regulation of energy homeostasis GO:2000505 9.72 LEPR MLXIPL
33 fatty acid homeostasis GO:0055089 9.72 INS MLXIPL XBP1
34 glucose metabolic process GO:0006006 9.72 ADIPOQ INS IRS2 LEP TNF
35 negative regulation of hormone secretion GO:0046888 9.71 ADIPOQ IL6
36 sexual reproduction GO:0019953 9.71 LEP LEPR
37 positive regulation of triglyceride biosynthetic process GO:0010867 9.71 NR1H3 SREBF1
38 positive regulation of glucose metabolic process GO:0010907 9.71 IRS1 IRS2
39 negative regulation of appetite GO:0032099 9.7 LEP PPARA
40 regulation of fatty acid metabolic process GO:0019217 9.7 PPARA SREBF1
41 regulation of bone remodeling GO:0046850 9.69 LEP LEPR
42 negative regulation of cholesterol storage GO:0010887 9.69 NR1H3 PPARA
43 positive regulation of fatty acid beta-oxidation GO:0032000 9.69 IRS1 IRS2 PPARA
44 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.68 IL6 TNF
45 negative regulation of lipid storage GO:0010888 9.67 IL6 LEP TNF
46 sterol homeostasis GO:0055092 9.66 NR1H3 XBP1
47 positive regulation of STAT protein import into nucleus GO:2000366 9.65 IL6 LEP
48 bone growth GO:0098868 9.65 LEP LEPR
49 leptin-mediated signaling pathway GO:0033210 9.65 ADIPOR1 LEP LEPR
50 regulation of fatty acid biosynthetic process GO:0042304 9.63 ADIPOQ ADIPOR1 ADIPOR2

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.83 ADIPOR1 ADIPOR2 ATF4 MLXIPL XBP1
2 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.77 ATF4 MLXIPL NR1H3 PPARA SREBF1
3 transcription regulatory region DNA binding GO:0044212 9.71 ATF4 NR1H3 SREBF1 TNF
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.5 NR1H3 PPARA SREBF1
5 insulin receptor binding GO:0005158 9.33 INS IRS1 IRS2
6 adiponectin binding GO:0055100 9.26 ADIPOR1 ADIPOR2
7 adipokinetic hormone receptor activity GO:0097003 8.96 ADIPOR1 ADIPOR2
8 sterol response element binding GO:0032810 8.62 NR1H3 SREBF1

Sources for Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA